171 related articles for article (PubMed ID: 31530564)
1. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Prevel R; Roubaud-Baudron C; Gourlain S; Jamme M; Peres K; Benhamou Y; Galicier L; Azoulay E; Poullin P; Provôt F; Maury E; Presne C; Hamidou M; Saheb S; Wynckel A; Servais A; Girault S; Delmas Y; Chatelet V; Augusto JF; Mousson C; Perez P; Halimi JM; Kanouni T; Lautrette A; Charvet-Rumpler A; Deligny C; Chauveau D; Veyradier A; Coppo P
Blood; 2019 Dec; 134(24):2209-2217. PubMed ID: 31530564
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age.
Rottenstreich A; Dor S; Keren-Politansky A; Sarig G; Nadir Y; Ellis M; Spectre G; Kirgner I; Pikovsky O; Arad A; Dann EJ; Kalish Y
J Thromb Thrombolysis; 2021 Jan; 51(1):187-193. PubMed ID: 32388825
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura.
Lu R; Zheng XL
Thromb Haemost; 2022 Mar; 122(3):344-352. PubMed ID: 33984867
[TBL] [Abstract][Full Text] [Related]
4. Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores.
Baysal M; Hindilerden F; Ümit EG; Demir AM; Keklik Karadağ F; Saydam G; Akpınar S; Turgut B; Özkocaman V; Özkalemkaş F; Çiftçiler R; Özlü C; Demircioğlu S; İpek Y; Diz Küçükkaya R
Turk J Haematol; 2023 Dec; 40(4):251-257. PubMed ID: 37791641
[TBL] [Abstract][Full Text] [Related]
5. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom.
Holmes S; Podger L; Bottomley C; Rzepa E; Bailey KMA; Chandler F
Hematology; 2021 Dec; 26(1):465-472. PubMed ID: 34238132
[TBL] [Abstract][Full Text] [Related]
6. [Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange].
Benhamou Y; Sauvètre G; Grangé S; Veyradier A; Coppo P
Rev Med Interne; 2020 Dec; 41(12):809-813. PubMed ID: 32727695
[TBL] [Abstract][Full Text] [Related]
7. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives].
Prevel R; Roubaud-Baudron C; Tellier E; Le Besnerais M; Kaplanski G; Veyradier A; Benhamou Y; Coppo P;
Rev Med Interne; 2021 Mar; 42(3):202-209. PubMed ID: 33455838
[TBL] [Abstract][Full Text] [Related]
8. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
9. Immune thrombotic thrombocytopenic purpura in patients over 60 years of age: Diagnostic pitfalls and treatment strategy.
Lester W
Br J Haematol; 2023 Dec; 203(5):704-705. PubMed ID: 37749067
[TBL] [Abstract][Full Text] [Related]
10. The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review.
Joseph A; Joly BS; Picod A; Veyradier A; Coppo P
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176509
[TBL] [Abstract][Full Text] [Related]
11. Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura.
Renaud A; Caristan A; Seguin A; Agard C; Blonz G; Canet E; Eveillard M; Godmer P; Graveleau J; Lecouffe-Desprets M; Maisonneuve H; Perrin F; Hamidou M; Néel A
PLoS One; 2021; 16(11):e0260196. PubMed ID: 34797873
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.
Sui J; Lu R; Halkidis K; Kocher NK; Cao W; Marques MB; Zheng XL
J Thromb Haemost; 2021 Feb; 19(2):370-379. PubMed ID: 33188723
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure.
Joseph A; Eloit M; Azoulay E; Kaplanski G; Provot F; Presne C; Wynckel A; Grangé S; Rondeau É; Pène F; Delmas Y; Lautrette A; Barbet C; Mousson C; Coindre JP; Perez P; Jamme M; Augusto JF; Poullin P; Jacobs F; El Karoui K; Vigneau C; Ulrich M; Kanouni T; Le Quintrec M; Hamidou M; Ville S; Charvet-Rumpler A; Ojeda-Uribe M; Godmer P; Fremeaux-Bacchi V; Veyradier A; Halimi JM; Coppo P
Res Pract Thromb Haemost; 2022 May; 6(4):e12702. PubMed ID: 35599703
[TBL] [Abstract][Full Text] [Related]
14. Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Lin C; Memon R; Sui J; Zheng XL
Cerebrovasc Dis Extra; 2021; 11(1):29-36. PubMed ID: 33601375
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
Lu R; Sui J; Zheng XL
Blood Adv; 2020 Nov; 4(21):5378-5388. PubMed ID: 33141886
[TBL] [Abstract][Full Text] [Related]
16. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
17. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus.
Letchumanan P; Ng HJ; Lee LH; Thumboo J
Rheumatology (Oxford); 2009 Apr; 48(4):399-403. PubMed ID: 19202160
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States.
Adeyemi A; Razakariasa F; Chiorean A; de Passos Sousa R
Res Pract Thromb Haemost; 2022 Aug; 6(6):e12802. PubMed ID: 36176310
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study.
Huang SS; Pavenski K; Lee TY; Jurkiewicz MT; Bharatha A; Thiessen JD; St Lawrence K; Théberge J; Mandzia J; Barth D; Licht C; Patriquin CJ
Blood Adv; 2021 Oct; 5(20):4211-4218. PubMed ID: 34521110
[TBL] [Abstract][Full Text] [Related]
20. Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura.
Joffre J; Raia L; Urbina T; Bonny V; Gabarre P; Missri L; Baudel JL; Coppo P; Guidet B; Maury E; Ait-Oufella H
Crit Care; 2023 Mar; 27(1):116. PubMed ID: 36944989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
